Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis

Stroke

Volumn 48, Issue 9, 2017, Pages 2494-2503

  Ntaios, George ^a   Papavasileiou, Vasileios ^b   Makaritsis, Konstantinos ^a   Vemmos, Konstantinos ^c   Michel, Patrik ^d   Lip, Gregory Y H ^e,f  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Hellenic Cardiovascular Research Society   (Greece)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f AALBORG UNIVERSITY   (Denmark)

Author keywords

apixaban; atrial fibrillation; dabigatran; embolism; rivaroxaban; warfarin

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; WARFARIN;

ARTICLE; ATRIAL FIBRILLATION; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; DEATH; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; NEUROPROTECTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; BLEEDING; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; DABIGATRAN; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; WARFARIN;

EID: 85024484704     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.117.017549     Document Type: Article

References (43)

1. Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? BMJ. 1998;316:201.
2. Ntaios G, Bornstein NM, Caso V, Christensen H, De Keyser J, Diener HC, et al; European Stroke Organisation. The European Stroke Organisation Guidelines: a standard operating procedure. Int J Stroke. 2015;10(suppl A100):128-135. doi: 10.1111/ijs.12583.
3. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293-2297. doi: 10.1056/NEJMsb1609216.
4. Husted S, de Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, et al; ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost. 2014;111:781-782. doi: 10.1160/TH14-03-0228.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. doi: 10.1056/ NEJMoa1009638.
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039.
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104. doi: 10.1056/NEJMoa1310907.
9. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
10. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011;64:407-415. doi: 10.1016/j. jclinepi.2010.07.017.
11. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.
12. Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016;115:152-160. doi: 10.1160/TH15-03-0247.
13. Bengtson LGS, Lutsey PL, Chen LY, MacLehose RF, Alonso A. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol. 2017;69:868-876. doi: 10.1016/j.jjcc.2016.08.010.
14. Bouillon K, Bertrand M, Maura G, Blotière PO, Ricordeau P, Zureik M. Risk of bleeding and arterial thromboembolism in patients with nonvalvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015;2:e150-e159. doi: 10.1016/S2352-3026(15)00027-7.
15. Chan YH, Kuo CT, Yeh YH, Chang SH, Wu LS, Lee HF, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;68:1389-1401. doi: 10.1016/j.jacc.2016.06.062.
16. Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. Stroke. 2016;47:441-449. doi: 10.1161/STROKEAHA.115.011476.
17. Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;32:2047-2053. doi: 10.1080/03007995. 2016.1237937.
18. Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf. 2016;25:1236-1244. doi: 10.1002/pds.4034.
19. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157-164. doi: 10.1161/ CIRCULATIONAHA.114.012061.
20. Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3:28-36. doi: 10.1093/ehjcvp/pvw031.
21. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175:18-24. doi: 10.1001/jamainternmed.2014.5398.
22. Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30:1317-1325. doi: 10.1185/03007995.2014.907140.
23. Larsen TB, Skjøth F, Nielsen PB, Kjaldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
24. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in realworld us patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4:pii: e001798. doi: 10.1161/ JAHA.115.001798.
25. Lip GY, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. Int J Clin Pract. 2016;70:752-763. doi: 10.1111/ijcp.12863.
26. Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975-986. doi: 10.1160/TH16-05-0403.
27. Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015;132:1252-1260. doi: 10.1161/ CIRCULATIONAHA.115.015710.
28. Nishtala PS, Gnjidic D, Jamieson HA, Hanger HC, Kaluarachchi C, Hilmer SN. 'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. Int J Cardiol. 2016;203:746-752. doi: 10.1016/j.ijcard.2015.11.067.
29. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114:1277-1289. doi: 10.1160/TH15-06-0497.
30. Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3:pii: e002758. doi: 10.1136/bmjopen-2013-002758.
31. Staerk L, Fosbøl EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2017;38:907-915. doi: 10.1093/eurheartj/ehw496.
32. Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114:1290-1298. doi: 10.1160/ TH15-06-0453.
33. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:pii: e003725. doi: 10.1161/JAHA.116.003725.
34. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GY. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127:650-656 e655. doi: 10.1016/j.amjmed.2014.01.031.
35. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjoth F, Lane DA, Lip GY. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med. 2014;127:1172-1178 e1175. doi: 10.1016/j.amjmed.2014.07.023.
36. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjoth F, Rosenzweig M, Lane DA, et al. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. American J Med. 2014;127:329-336 e324. doi: 10.1016/j.amjmed.2013.12.005.
37. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264-2273. doi: 10.1016/j.jacc.2013.03.020.
38. Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, Cram P. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med. 2014;127:1179-1185. doi: 10.1016/j.amjmed.2014.07.024.
39. Giglio AF, Basile E, Santangeli P, Di Biase L, Trotta F, Natale A. Increased risk of myocardial infarction with dabigatran: fact or fiction? J Cardiovasc Med (Hagerstown). 2014;15:19-26. doi: 10.2459/ JCM.0b013e328364beb8.
40. Artang R, Rome E, Nielsen JD, Vidaillet HJ. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol. 2013;112:1973-1979. doi: 10.1016/j.amjcard.2013.08.027.
41. Hohnloser SH, Lip GYH. Dabigatran and myocardial infarction. Chest. 2015;147:e70-e71. doi: 10.1378/chest.14-2534.
42. Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3:e000515. doi: 10.1161/JAHA. 113.000515.
43. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962. doi: 10.1093/eurheartj/ehw210.